NCT02926027View on ClinicalTrials.gov

Effect of Vascepa on Improving Coronary Atherosclerosis in People With High Triglycerides Taking Statin Therapy

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 28, 2017

Primary Completion Date

May 15, 2020

Study Completion Date

August 15, 2020

Conditions
Hypertriglyceridemia
Interventions
DRUG

Vascepa

Vascepa is a an Eicosapentaenoic acid (EPA), an omega-3 polyunsaturated fatty acid.

DRUG

placebo

placebo

Trial Locations (2)

84157

Intermountain Medical Center, Intermountain Heart Institute, Murray

90502

Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute), Torrance

All Listed Sponsors
collaborator

Intermountain Research and Medical Foundation

OTHER

lead

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

OTHER

NCT02926027 - Effect of Vascepa on Improving Coronary Atherosclerosis in People With High Triglycerides Taking Statin Therapy | Biotech Hunter | Biotech Hunter